TY  - JOUR
A1  - Schmidt, Stefanie
A1  - Abinzano, Florencia
A1  - Mensinga, Anneloes
A1  - Teßmar, Jörg
A1  - Groll, Jürgen
A1  - Malda, Jos
A1  - Levato, Riccardo
A1  - Blunk, Torsten
T1  - Differential production of cartilage ECM in 3D agarose constructs by equine articular cartilage progenitor cells and mesenchymal stromal cells
JF  - International Journal of Molecular Sciences
N2  - Identification of articular cartilage progenitor cells (ACPCs) has opened up new opportunities for cartilage repair. These cells may be used as alternatives for or in combination with mesenchymal stromal cells (MSCs) in cartilage engineering. However, their potential needs to be further investigated, since only a few studies have compared ACPCs and MSCs when cultured in hydrogels. Therefore, in this study, we compared chondrogenic differentiation of equine ACPCs and MSCs in agarose constructs as monocultures and as zonally layered co-cultures under both normoxic and hypoxic conditions. ACPCs and MSCs exhibited distinctly differential production of the cartilaginous extracellular matrix (ECM). For ACPC constructs, markedly higher glycosaminoglycan (GAG) contents were determined by histological and quantitative biochemical evaluation, both in normoxia and hypoxia. Differential GAG production was also reflected in layered co-culture constructs. For both cell types, similar staining for type II collagen was detected. However, distinctly weaker staining for undesired type I collagen was observed in the ACPC constructs. For ACPCs, only very low alkaline phosphatase (ALP) activity, a marker of terminal differentiation, was determined, in stark contrast to what was found for MSCs. This study underscores the potential of ACPCs as a promising cell source for cartilage engineering.
KW  - ACPC
KW  - chondroprogenitors
KW  - tissue engineering
KW  - MSC
KW  - agarose
KW  - hypoxia
KW  - ECM
KW  - co-culture
KW  - zonal
KW  - cartilage
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236180
SN  - 1422-0067
VL  - 21
IS  - 19
ER  - 
TY  - JOUR
A1  - Herrmann, Marietta
A1  - Diederichs, Solvig
A1  - Melnik, Svitlana
A1  - Riegger, Jana
A1  - Trivanović, Drenka
A1  - Li, Shushan
A1  - Jenei-Lanzl, Zsuzsa
A1  - Brenner, Rolf E.
A1  - Huber-Lang, Markus
A1  - Zaucke, Frank
A1  - Schildberg, Frank A.
A1  - Grässel, Susanne
T1  - Extracellular Vesicles in Musculoskeletal Pathologies and Regeneration
JF  - Frontiers in Bioengineering and Biotechnology
N2  - The incidence of musculoskeletal diseases is steadily increasing with aging of the population. In the past years, extracellular vesicles (EVs) have gained attention in musculoskeletal research. EVs have been associated with various musculoskeletal pathologies as well as suggested as treatment option. EVs play a pivotal role in communication between cells and their environment. Thereby, the EV cargo is highly dependent on their cellular origin. In this review, we summarize putative mechanisms by which EVs can contribute to musculoskeletal tissue homeostasis, regeneration and disease, in particular matrix remodeling and mineralization, pro-angiogenic effects and immunomodulatory activities. Mesenchymal stromal cells (MSCs) present the most frequently used cell source for EV generation for musculoskeletal applications, and herein we discuss how the MSC phenotype can influence the cargo and thus the regenerative potential of EVs. Induced pluripotent stem cell-derived mesenchymal progenitor cells (iMPs) may overcome current limitations of MSCs, and iMP-derived EVs are discussed as an alternative strategy. In the last part of the article, we focus on therapeutic applications of EVs and discuss both practical considerations for EV production and the current state of EV-based therapies.
KW  - extracellular vesicles
KW  - exosomes
KW  - musculoskeletal diseases
KW  - MSC
KW  - iMP
KW  - cell-free therapeutics
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222882
SN  - 2296-4185
VL  - 8
ER  -